Compare Figs Inc (FIGS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Repligen Corporation Common Stock — how do they compare? Figs Inc trades at $18.62 (market cap $2.99B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.7× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and Repligen Corporation Common Stock for 0 Days on average.
| FIGS | RGEN | |
|---|---|---|
Market Cap | $2.99B | $11.14B |
Volume | 6,721,481 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $194.57 |
52-Week Low | $7.38 | $102.87 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.75B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $18.63, up 4.9% today, showing strong momentum with three consecutive quarterly earnings beats. The company demonstrates robust fundamentals with 68.9% gross margins and accelerating revenue growth from $556M in 2024 to projected $710M in 2026. Technical indicators show bullish momentum with the stock trading near resistance at $19, though RSI levels suggest potential overbought conditions. Recent news highlights international expansion success with 67% Q2 international sales growth and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential to $18 target, though the premium valuation (P/E 54.6) requires continued execution. Key risks include rich valuation multiples and competitive pressures in healthcare apparel. The combination of strong earnings momentum, international growth, and bullish technicals supports further upside if the company maintains its growth trajectory.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
